Ixosin (1-12)

General Information


DCTPep ID  DCTPep02863

Peptide Name   Ixosin (1-12)

Sequence  GLHKVMREVLGY

Sequence Length  12

UniProt ID  Q2LKX9 

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

ACP Tumor active peptide



Activity Information


Cell Line Disease Activity Assay Testing Time Literature
HeLa Human papillomavirus-related endocervical adenocarcinoma 27% Killing=128 µM MTT assay 24 h 1

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  HEK-293: 3% Killing>128 µM

Target  Not available

Affinity  Not available

Mechanism  Not available



Structure Information


PDB ID  Not available

Predicted Structure  Not available

(Please note that there is the predicted structure, predicted by AlphaFold)

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Amidation

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C63H104N18O16S1

Absent amino acids  ACDFINPQSTW

Theoretical pI  8.60

Acidic residues  1

Basic residues  3

Polar residues  3

Molecular weight (Average)  1401.69

Molecular weight (Monoisotopic)  1400.76

Common amino acids  GLV

Net charge  2

Instability index (II)  8.47

Aliphatic index  113.33

Grand average of hydropathicity (GRAVY)  0.058

Half Life 
  30 hours (mammalian reticulocytes, in vitro).
  >20 hours (yeast, in vivo).
  >10 hours (Escherichia coli, in vivo).

Extinction coefficients 
  Ext. coefficient 1490
  Abs 0.1% (=1 g/l) 1.063

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 27622949

Title  Central Role of the Copper-Binding Motif in the Complex Mechanism of Action of Ixosin: Enhancing Oxidative Damage and Promoting Synergy with Ixosin B

Doi 10.1021/acsinfecdis.5b00140

Year  2016

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DBAASP ID  DBAASPR_17330

DCTPep is developed by Dr.Zheng's team.